Patrys Limited (PAB) fair value: what the stock is really worth
As of Oct 14, 2026: fair value of Patrys Limited A$0.02, price A$0.03, upside -20.0%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases.
Show more
Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and inflammatory diseases. The Company's portfolio includes an injectable quetiapine program for the treatment of delirium and its versatile deoxymab antibody platform, including PAT-DX1 and PAT-DX3, which is being developed for applications in inflammatory and autoimmune diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and cancers and/or metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.
Stock analysis
Patrys Limited (PAB) currently trades at A$0.0300, while our model-based Fair Value estimate is A$0.0240, 20.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Health Care sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Patrys Limited reported revenue of A$9.0K in FY2026 versus A$27.5K in FY2022, a compound −24.4%/yr. Reported net income was −A$3.4M in FY2026.
The share trades about 39% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Health Care peers we cover trades at 10% fair-value upside, at −20%, PAB screens richer than that median.
Fair Value models
Bear A$0.0240Fair Value A$0.0240Bull A$0.0240
Price A$0.0300 · Upside -20.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−98.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−85.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.0%
Start year 2021 (pandemic). Over 10 years: −29.0% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−9.5%
’14
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
’26
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21,303.8% (2021) → −38,103.2% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 604 stocks
Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score36 · Below median
Fair Value upside−20.0% · Above median
Profitability
Return on assets−35.8% · Bottom 25%
Growth and dividend
Revenue growth−93.2% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Patrys Limited Fair Value". https://www.fairvalue-calculator.com/stock/PAB
Frequently asked questions
Is Patrys Limited (PAB) overvalued or undervalued?
As of Oct 14, 2026, our model estimates a fair value of A$0.0240 versus a price of A$0.0300, about −20% upside (overvalued).
What is the fair value of PAB?
Our model-based fair value for Patrys Limited is A$0.0240 (as of Oct 14, 2026), built from audited fundamentals. The current price: A$0.0300.
What is the quality score of PAB?
Patrys Limited has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Patrys Limited (PAB)?
Our model-based price target is the fair value of A$0.0240 (as of Oct 14, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Patrys Limited stock forecast for 2026?
Our models put fair value at A$0.0240, about −20% upside versus a price of A$0.0300 (overvalued). The calculation is refreshed regularly with new filings.
What is the revenue of Patrys Limited (PAB)?
Patrys Limited reported trailing-twelve-month revenue of about A$9.0K (latest available figure, as of Oct 14, 2026).
What is the intrinsic value of Patrys Limited (PAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Patrys Limited it is A$0.0240 per share (as of Oct 14, 2026), against a price of A$0.0300. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Patrys Limited stock overvalued or undervalued in 2026?
As of Oct 14, 2026, PAB trades above its calculated fair value: price A$0.0300, fair value A$0.0240, a gap of about −20% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PAB?
No. The price is what the market pays today (A$0.0300); the fair value is what the company's own numbers justify (A$0.0240). For Patrys Limited the two are A$0.0060 per share apart. That gap is exactly why we show both numbers side by side.
How much is Patrys Limited worth?
The market values Patrys Limited at about A$12.3M (market capitalisation, as of Oct 14, 2026). Per share that is A$0.0300; our models calculate a fair value of A$0.0240 per share.
How solid is the balance sheet of Patrys Limited (PAB)?
Balance-sheet figures for Patrys Limited (as of Oct 14, 2026): return on equity −68.3%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is PAB from its 52-week high?
Patrys Limited trades at A$0.0300, about 39% below its 52-week high of A$0.0490 and 20% above the low of A$0.0250 (as of Oct 14, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0240 is for.
Which stocks are comparable to Patrys Limited?
From the same area (Health Care) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Patrys Limited stock attractive at the current price?
The data as of Oct 14, 2026: price A$0.0300, calculated fair value A$0.0240 (−20%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PAB calculated?
We run Patrys Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0240, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Patrys Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Patrys Limited (PAB)?
The closing price on Oct 14, 2026 was A$0.0300. Our model-based fair value is A$0.0240, about −20% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Patrys Limited right now?
The price sits above even our optimistic bull case (A$0.0240). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of Patrys Limited
How large is the market capitalisation of Patrys Limited (PAB)?
The market capitalisation of Patrys Limited is A$12.3M (≈ $8.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Patrys Limited (PAB)?
Earnings per share at Patrys Limited are A$−0.0200. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Patrys Limited (PAB)?
The return on equity (ROE) of Patrys Limited is −68.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Patrys Limited (PAB)?
On an EBIT basis the return on assets of Patrys Limited is −96.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Patrys Limited (PAB)?
The operating margin of Patrys Limited is −5,896% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Patrys Limited (PAB)?
Revenue at Patrys Limited is growing −93.2% versus a year earlier (3y avg −85.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Patrys Limited (PAB) generate?
The free cash flow of Patrys Limited is −A$2.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Patrys Limited (PAB) hold?
Patrys Limited holds more cash than debt, A$3.4M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Patrys Limited in the live analysis
One click puts Patrys Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.
